Tagged with Roche

Mexico Mexico’s pharma market, the second largest in Latin America and among the top 15 globally, is set to top USD 13 billion in sales by 2028. Despite the encouraging numbers, some industry insiders are bemoaning the current government’s healthcare missteps along with the country’s low public spending and regulatory hurdles.…

Global COVID-19 vaccines and treatments continue to make headline news and bring in huge revenues for sponsor companies, but Pharma Exec’s 2022 Top 50 Companies ranking suggests that many non-COVID products are once more driving big gains. Against the backdrop of an increasingly fraught geopolitical climate and patent landscape, the next…

USA Pharma companies have become vocal about social issues in recent years, championing access and affordability and launching initiatives to address diversity, but in the weeks since the United States’ Supreme Court’s overturn of the Roe v. Wade ruling on abortion the industry’s reaction has been far from consistent. While certain…

Global Swiss pharma giant, Roche, has announced a change in leadership that will see Severin Schwan replaced by diagnostics division head, Thomas Schinecker, after a 14-year stint as CEO. Schinecker, who became a contender for the role by leading the company’s efforts in developing a COVID-19 test kit, growing sales by…

Global At the recent Global Biopharma press briefing on COVID-19, held by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), industry leaders took on the issue of vaccine inequity, challenging the view that intellectual property waivers could be the answer. 13.7 billion doses of vaccines have been delivered and 11…

Ukraine Russia’s invasion of Ukraine has been roundly condemned by the pharmaceutical industry and almost all Big Pharmas have pledged humanitarian support to Ukraine. However, not all companies have followed the lead of businesses in other industries in severing ties with Russia, citing the importance of continuing to supply essential medicines…

Global Pfizer’s record-breaking year set the stage for a sound financial year for Big Pharma’s top ten, whose revenue grew on average 19.8 percent in 2021. Posting sales of over USD 80 billion, Pfizer pulled away from second placed Roche and is aiming to break the USD 100 billion barrier in…

Europe At the recent FT webinar, ‘Supporting Pharma Innovation in Europe’, high-level representatives from Roche, Bayer, and the European Commission weighed in on how European pharma’s competitive position on innovation is being challenged and the policy measures that need to be enacted to solve this issue. Read on for five key…

Global The oncology field has exploded in the past 20 years and pharma companies now have a wide range of approaches available to them as they look to identify, treat, and in some cases even cure, cancer patients. Here, five industry experts weigh in on the exciting new tools and technology…

Global After 20 years, Novartis will no longer own one third of Roche’s shares after the two Swiss pharma giants agreed to a transaction worth USD 20.7 billion. While Roche touted the deal as the regaining of “full strategic flexibility”, Novartis argued that it was the right time to “monetize” its…

China In a big career move on a personal level and a sign of China’s continuing significance to global pharma, Hong Chow has left her role as General Manager for Roche Pharma in China to take on an expanded role at German giant Merck KGaA.   Chow will join Merck’s Healthcare…

China In May 2021 Swiss giant Roche launched the ‘Roche Accelerator’ in Shanghai, a USD 31.1 million investment aiming to foster and capitalise on China’s burgeoning life sciences start-up ecosystem.   The 5000 square metre project, Roche’s first such in-house accelerator globally, builds on the company’s sizeable existing R&D presence in…